Vaccine production not perfect but our drug saves lives, AstraZeneca says, as Africa backs COVID-19 shot

(Correcting to show CEO was referring to vaccine production not efficacy in headline, first and 4th paragraphs) By Pushkala Aripaka and Ludwig Burger (Reuters) - The production of AstraZeneca's COVID-19 vaccine has not been perfect but the shot will have a big impact on the pandemic, its chief executive said on Thursday, as the drugmaker pledged to double output by April and the African Union gave its backing for the shot. The two-dose inoculation, developed with Oxford University, has been hailed as a 'vaccine for the world' because it is cheaper and easier to distribute than some rivals. But its rapid approval in Europe and elsewhere has been clouded by doubts over its most effective dosage and interval between doses.

Reuters February 13, 2021 00:06:44 IST
Vaccine production not perfect but our drug saves lives, AstraZeneca says, as Africa backs COVID-19 shot

COVID-19 shot" src="https://images.firstpost.com/wp-content/uploads/reuters/02-2021/13/2021-02-11T143433Z_5_LYNXMPEH1A0EH_RTROPTP_2_HEALTH-CORONAVIRUS-VACCINE-OXFORD.jpg" alt="Vaccine production not perfect but our drug saves lives AstraZeneca says as Africa backs COVID19 shot" width="300" height="225" />

(Correcting to show CEO was referring to vaccine production not efficacy in headline, first and 4th paragraphs)

By Pushkala Aripaka and Ludwig Burger

(Reuters) - The production of AstraZeneca's COVID-19 vaccine has not been perfect but the shot will have a big impact on the pandemic, its chief executive said on Thursday, as the drugmaker pledged to double output by April and the African Union gave its backing for the shot.

The two-dose inoculation, developed with Oxford University, has been hailed as a "vaccine for the world" because it is cheaper and easier to distribute than some rivals.

But its rapid approval in Europe and elsewhere has been clouded by doubts over its most effective dosage and interval between doses.

Data at the weekend also showed it was less effective against a fast-spreading variant of the virus in South Africa, prompting the country to pause rollout of the shot. The company has also been embroiled in a row with the European Union over supply delays but Soriot said AstraZeneca was working to ramp up output as fast as possible.

"Is it perfect? No, it's not perfect, but it's great. Who else is making 100 million doses in February?" CEO Pascal Soriot said on a conference call about the vaccine.

"We're going to save thousands of lives and that's why we come to work everyday."

The company said it aimed to produce more than 200 million doses per month by April, double this month's level as the world tries to tame a pandemic that has killed 2.35 million.

Head of operations Pam Cheng said on the call that the group was working to further expand global capacity and productivity.

AstraZeneca has set a target to produce 3 billion doses this year, with India's Serum Institute making much of that aimed at poorer nations.

On Wednesday, the company enlisted Germany's IDT Biologika as a contract manufacturer, but the bulk of IDT's contribution will only come onstream late next year.

AstraZeneca said it expected much-anticipated data from the U.S. trial of the vaccine before the end of March, and that it was confident the shot offered relatively good protection against severe disease and death for the South African variant. Its disappointing results were against milder cases.

However, after rising to become Britain's most valuable company last summer, the company has now slipped to sixth, in a move some analysts attribute to doubts over the vaccine.

"In a year or two we will look back and everybody will realise we made a big impact," Soriot said.

POSTER CHILD

AstraZeneca's shares were up 0.95% in afternoon trade, paring some earlier gains, after the company forecast a pick up in earnings growth this year on strong demand for its cancer and other new therapies.

It has pledged not to make any money from its COVID-19 vaccine during the pandemic.

It has been a tumultuous week for the drugmaker after South Africa put on hold giving the shot to its citizens, choosing one developed by its U.S. rival Johnson & Johnson instead.

That came after the trial data raised concerns about the AstraZeneca vaccine's effectiveness on mild symptoms from the more infectious 501Y.V2 variant of the virus dominant in South Africa, which has spread to 41 nations around the world.

Despite that blow, the World Health Organization endorsed the British vaccine on Wednesday and the African Union said it would target its use in countries that have not reported cases of the variant.

Kenya and Morocco are also planning to administer it.

AstraZeneca said it expected 2021 revenues to rise by a low teens percentage and core earnings of $4.75 to $5.00 per share, as it beat expectations for fourth-quarter sales.

The earnings guidance equates to 18-24% growth, after 15% in 2020, but was a little lower than the $5.10 per share analysts were expecting, as the company flagged more spending this year.

The COVID-19 vaccine is not included in the guidance and the company said its sales would be reported separately from the first quarter of 2021.

While public interest is focused on the vaccine, AstraZeneca's core business of diabetes, heart, kidney, and cancer medicines has been steadily growing, helping the company to turn around years of decline.

"The company is arguably the poster child for big pharma turnarounds," said Third Bridge senior analyst Sebastian Skeet.

(Reporting by Pushkala Aripaka and Ludwige Burger. Editing by Josephine Mason and Jon Boyle)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply

also read

Ethiopia's regional Tigray forces name conditions for peace with government
World

Ethiopia's regional Tigray forces name conditions for peace with government

NAIROBI (Reuters) - Forces fighting Ethiopia's military in the Tigray region laid out eight conditions on Friday for beginning peace talks, including the appointment of an international mediator and unimpeded access for humanitarian aid. Prime Minister Abiy Ahmed ordered air strikes and a ground offensive against the Tigray People's Liberation Front (TPLF) - the former ruling party in the northern region - after regional forces attacked federal army bases in the region on Nov.

Citigroup considering divestiture of some foreign consumer units - Bloomberg Law
Business

Citigroup considering divestiture of some foreign consumer units - Bloomberg Law

(Reuters) - Citigroup Inc is considering divesting some international consumer units, Bloomberg Law reported on Friday, citing people familiar with the matter. The discussions are around divesting units across retail banking in the Asia-Pacific region, the report https://bit.ly/3pD57WP said

Biden tours Pfizer vaccine plant as drugmaker promises to double supply
World

Biden tours Pfizer vaccine plant as drugmaker promises to double supply

By Alexandra Alper and Michael Erman PORTAGE, Mich. (Reuters) - U.S